3B Blackbio DX Ltd Q1 FY27 results (latest), Apr–Jun 2026 →See revenue, profit and what management said. You are viewing Q4 FY25.
3B

3B Blackbio DX Ltd

Q4 FY25Healthcare Services

3B Blackbio DX Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹22Cr
−4.3% YoY
−12% QoQ
Net profit
₹8Cr
−11.1% YoY
−38.5% QoQ
Margin
35%
−8 pp YoY
−24 pp QoQ

3B Blackbio DX Ltd Q4 FY25 key numbers

Revenue
Consolidated sales in Q4 2024-25: INR 1,947.96 Lakh vs INR 1,906.48 Lakh in Q4 2023-24 (including TRUPCR Europe Limited sales of INR 187.18 Lakh).

As stated in 3B Blackbio DX Ltd's Q4 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on 3B Blackbio DX Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹1,406
Market cap₹1.1K Cr
P/E20.4

The short version

Q4 FY 2024-25 revenue: INR 2,249.51 Lakh; Q4 FY 2023-24 revenue: INR 2,299.80 Lakh (slight YoY decrease). EBITDA for Q4 2024-25: INR 1,253.91 Lakh - Year-on-year change: Decrease from INR 1,372.90 Lakh (Q4 2023-24) - Profit After Tax (PAT) for Q4 2024-25: INR 803.55 Lakh - Year-on-year change: Decrease from INR 879.03 Lakh (Q4 2023-24) - Revenue from Operations for Q4 2024-25: INR 2,249.51 Lakh - Year-on-year change: Slight decrease from INR 2,299.80 Lakh (Q4 2023-24)

From 3B Blackbio DX Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q4 FY 2024-25 revenue: INR 2,249.51 Lakh; Q4 FY 2023-24 revenue: INR 2,299.80 Lakh (slight YoY decrease).
  • Consolidated sales in Q4 2024-25: INR 1,947.96 Lakh vs INR 1,906.48 Lakh in Q4 2023-24 (including TRUPCR Europe Limited sales of INR 187.18 Lakh).
  • Export sales Q4 2024-25: INR 410.40 Lakh vs INR 290.15 Lakh in Q4 2023-24 (substantial increase).
  • UK subsidiary (TRUPCR Europe Limited) revenue FY 2024-25: GBP 1,287,580, a 94% increase over FY 2023-24 GBP 664,059. Projected 20-25% growth in FY 2025-26.

2 more points from 3B Blackbio DX Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 41). - New products are being designed and launched to meet increasing market needs and maintain growth momentum (Page 41). - A joint venture in Manchester, UK, may receive funding deployment depending on need (Page 41). - Expansion focus appears on enhancing current manufacturing/R&D capacities rather than new plants (Page 41). Funding for joint venture activities in the UK is planned as required.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

It mentions: - Strong order inflow in the Middle East reflecting growing market traction (Page 20). - Long-term contracts (15+ contracts) under the Reagent-Rental Model projecting steady business worth 20%-25% of total revenue (Page 40). - Some Q4 2024-25 orders from TRUPCR Europe were shifted to Q1 2025 due to internal process delays at key customers (Page 16).

3B Blackbio DX Ltd — Quarterly revenue & net profit

Revenue Net profit
Sep 2024Q2 FY25
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26

3B Blackbio DX Ltd Q4 FY25 results — key figures

3B Blackbio DX Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue2223-4.3%25-12%
Operating profit (EBITDA)810-20%15-46.7%
Operating margin35%43%-8 pp59%-24 pp
Profit before tax1314-7.1%18-27.8%
Net profit (PAT)89-11.1%13-38.5%
EPS (₹)9.7910.33-5.2%15.61-37.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Apollo Hospitals (Q4 FY25)

    . Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Shalby (Q4 FY25)

    Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…

  • Narayana Hrudaya (Q4 FY25)

    Capex is split between regular maintenance/replacement (~INR 300 crores) and new greenfield/brownfield capacity (~INR 450 crores) with some variability based…

  • Healthcare Global Enterprises (Q4 FY25)

    FY '25 revenue grew 16% to INR 2,223 crores; Q4 revenue rose 18% YoY to INR 585 crores. Key concall takeaways from Healthcare Global Enterprises Ltd's Q4 FY25…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were 3B Blackbio DX Ltd Q4 FY25 results?

Q4 FY 2024-25 revenue: INR 2,249.51 Lakh; Q4 FY 2023-24 revenue: INR 2,299.80 Lakh (slight YoY decrease). EBITDA for Q4 2024-25: INR 1,253.91 Lakh - Year-on-year change: Decrease from INR 1,372.90 Lakh (Q4 2023-24) - Profit After Tax (PAT) for Q4 2024-25: INR 803.55 Lakh - Year-on-year change: Decrease from INR 879.03 Lakh (Q4 2023-24) - Revenue from Operations for Q4 2024-25: INR 2,249.51 Lakh - Year-on-year change: Slight decrease from INR 2,299.80 Lakh (Q4 2023-24)

What is 3B Blackbio DX Ltd share price analysis?

3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.

Is 3B Blackbio DX Ltd planning capital expenditure?

The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 41). - New products are being designed and launched to meet increasing market needs and maintain growth momentum (Page 41). - A joint venture in Manchester, UK, may receive funding deployment depending on need (Page 41). - Expansion focus appears on enhancing current manufacturing/R&D capacities rather than new plants (Page 41).

Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.